|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AHSG |
Gene summary for AHSG |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AHSG | Gene ID | 197 |
| Gene name | alpha 2-HS glycoprotein | |
| Gene Alias | A2HS | |
| Cytomap | 3q27.3 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | P02765 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 197 | AHSG | NAFLD1 | Human | Liver | NAFLD | 4.72e-08 | 7.86e-01 | -0.04 |
| 197 | AHSG | S43 | Human | Liver | Cirrhotic | 5.23e-08 | 3.19e-01 | -0.0187 |
| 197 | AHSG | HCC1_Meng | Human | Liver | HCC | 1.24e-88 | 1.41e+00 | 0.0246 |
| 197 | AHSG | HCC2_Meng | Human | Liver | HCC | 5.49e-12 | -4.14e-01 | 0.0107 |
| 197 | AHSG | cirrhotic1 | Human | Liver | Cirrhotic | 1.10e-03 | -2.69e-01 | 0.0202 |
| 197 | AHSG | cirrhotic2 | Human | Liver | Cirrhotic | 1.58e-06 | -1.74e-01 | 0.0201 |
| 197 | AHSG | HCC1 | Human | Liver | HCC | 4.70e-48 | 8.85e+00 | 0.5336 |
| 197 | AHSG | HCC2 | Human | Liver | HCC | 9.14e-60 | 8.58e+00 | 0.5341 |
| 197 | AHSG | Pt13.a | Human | Liver | HCC | 1.83e-06 | 1.64e-01 | 0.021 |
| 197 | AHSG | Pt13.b | Human | Liver | HCC | 3.61e-04 | -2.43e-01 | 0.0251 |
| 197 | AHSG | Pt14.a | Human | Liver | HCC | 8.96e-18 | 1.18e+00 | 0.0169 |
| 197 | AHSG | Pt14.b | Human | Liver | HCC | 8.91e-29 | 9.45e-01 | 0.018 |
| 197 | AHSG | Pt14.d | Human | Liver | HCC | 3.20e-18 | 6.28e-01 | 0.0143 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00713755 | Liver | NAFLD | cellular response to peptide hormone stimulus | 65/1882 | 290/18723 | 3.95e-10 | 9.62e-08 | 65 |
| GO:19016536 | Liver | NAFLD | cellular response to peptide | 71/1882 | 359/18723 | 1.82e-08 | 2.09e-06 | 71 |
| GO:00328695 | Liver | NAFLD | cellular response to insulin stimulus | 47/1882 | 203/18723 | 3.60e-08 | 3.63e-06 | 47 |
| GO:00434346 | Liver | NAFLD | response to peptide hormone | 76/1882 | 414/18723 | 1.51e-07 | 1.09e-05 | 76 |
| GO:00458617 | Liver | NAFLD | negative regulation of proteolysis | 66/1882 | 351/18723 | 4.02e-07 | 2.58e-05 | 66 |
| GO:00328685 | Liver | NAFLD | response to insulin | 53/1882 | 264/18723 | 6.99e-07 | 3.95e-05 | 53 |
| GO:00082863 | Liver | NAFLD | insulin receptor signaling pathway | 27/1882 | 116/18723 | 2.50e-05 | 6.76e-04 | 27 |
| GO:0002526 | Liver | NAFLD | acute inflammatory response | 26/1882 | 112/18723 | 3.68e-05 | 9.23e-04 | 26 |
| GO:00513467 | Liver | NAFLD | negative regulation of hydrolase activity | 62/1882 | 379/18723 | 8.11e-05 | 1.66e-03 | 62 |
| GO:00525477 | Liver | NAFLD | regulation of peptidase activity | 72/1882 | 461/18723 | 1.03e-04 | 2.03e-03 | 72 |
| GO:00525487 | Liver | NAFLD | regulation of endopeptidase activity | 67/1882 | 432/18723 | 2.17e-04 | 3.70e-03 | 67 |
| GO:0046626 | Liver | NAFLD | regulation of insulin receptor signaling pathway | 16/1882 | 66/18723 | 6.66e-04 | 8.61e-03 | 16 |
| GO:00109517 | Liver | NAFLD | negative regulation of endopeptidase activity | 42/1882 | 252/18723 | 7.29e-04 | 9.29e-03 | 42 |
| GO:0006953 | Liver | NAFLD | acute-phase response | 13/1882 | 49/18723 | 8.43e-04 | 1.03e-02 | 13 |
| GO:00104667 | Liver | NAFLD | negative regulation of peptidase activity | 43/1882 | 262/18723 | 8.76e-04 | 1.07e-02 | 43 |
| GO:1900076 | Liver | NAFLD | regulation of cellular response to insulin stimulus | 15/1882 | 64/18723 | 1.40e-03 | 1.57e-02 | 15 |
| GO:0050764 | Liver | NAFLD | regulation of phagocytosis | 19/1882 | 95/18723 | 2.61e-03 | 2.41e-02 | 19 |
| GO:0050766 | Liver | NAFLD | positive regulation of phagocytosis | 14/1882 | 66/18723 | 5.28e-03 | 4.08e-02 | 14 |
| GO:005254712 | Liver | Cirrhotic | regulation of peptidase activity | 185/4634 | 461/18723 | 1.32e-13 | 1.09e-11 | 185 |
| GO:005254812 | Liver | Cirrhotic | regulation of endopeptidase activity | 172/4634 | 432/18723 | 2.12e-12 | 1.58e-10 | 172 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AHSG | SNV | Missense_Mutation | c.875N>T | p.Gly292Val | p.G292V | P02765 | protein_coding | tolerated(0.34) | benign(0.001) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| AHSG | SNV | Missense_Mutation | novel | c.186N>T | p.Gln62His | p.Q62H | P02765 | protein_coding | deleterious(0.01) | probably_damaging(0.951) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| AHSG | insertion | Nonsense_Mutation | novel | c.998_999insCTTTGCAAATAAAAATGTATAATGTGAGGAAATTGGGTGCCA | p.Val333_Ser334insPheAlaAsnLysAsnValTerCysGluGluIleGlyCysGln | p.V333_S334insFANKNV*CEEIGCQ | P02765 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| AHSG | SNV | Missense_Mutation | c.904N>A | p.Ala302Thr | p.A302T | P02765 | protein_coding | tolerated(0.17) | benign(0.082) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| AHSG | SNV | Missense_Mutation | c.685N>G | p.Phe229Val | p.F229V | P02765 | protein_coding | deleterious(0) | possibly_damaging(0.886) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| AHSG | SNV | Missense_Mutation | rs766181399 | c.853G>A | p.Ala285Thr | p.A285T | P02765 | protein_coding | tolerated(0.58) | benign(0.005) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| AHSG | SNV | Missense_Mutation | novel | c.1075C>G | p.Pro359Ala | p.P359A | P02765 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AG-3883-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| AHSG | SNV | Missense_Mutation | rs774097503 | c.943G>A | p.Asp315Asn | p.D315N | P02765 | protein_coding | tolerated(0.18) | possibly_damaging(0.778) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| AHSG | SNV | Missense_Mutation | novel | c.431N>G | p.Lys144Arg | p.K144R | P02765 | protein_coding | tolerated(0.16) | benign(0.137) | TCGA-AJ-A2QL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| AHSG | SNV | Missense_Mutation | rs376930727 | c.331G>A | p.Glu111Lys | p.E111K | P02765 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |